Charles River Laboratories International (CRL) Accumulated Expenses (2009 - 2025)

Charles River Laboratories International's Accumulated Expenses history runs 17 years deep, the most recent figure standing at $268.9 million for Q4 2025.

• In Q4 2025, Accumulated Expenses rose 49.85% year-over-year to $268.9 million; the TTM figure through Dec 2025 stood at $268.9 million (up 49.85% YoY), while the FY2025 annual figure was $268.9 million, up 49.85% from the prior year.
• Accumulated Expenses for Q4 2025 stood at $268.9 million, roughly flat from $269.7 million in the prior quarter.
• The five-year high for Accumulated Expenses was $269.7 million in Q3 2025, with the low at $164.7 million in Q1 2021.
• The 5-year median for Accumulated Expenses is $217.0 million (2023), against an average of $213.5 million.
• The sharpest annual moves came in 2021 and 2024: Accumulated Expenses surged 58.74% in 2021, then fell 19.95% in 2024.
• Charles River Laboratories International's Accumulated Expenses stood at $228.8 million in 2021, then fell by 13.86% to $197.1 million in 2022, then grew by 8.23% to $213.3 million in 2023, then slipped by 15.88% to $179.4 million in 2024, then surged by 49.85% to $268.9 million in 2025.
• Business Quant data shows CRL's Accumulated Expenses at $268.9 million in Q4 2025, $269.7 million in Q3 2025, and $227.5 million in Q2 2025.